From : Keti Khizanishvili <keti.khizanishvili@gmail.com>
To : turkia babilina <bturkia@yahoo.com>; ketevan shermadini <shermadinik@yahoo.com>; Anzor tchavtchavadze <atchavtchavadze@moh.gov.ge>; kgagnidze@moh.gov.ge; Ekaterine Adamia <eadamia@moh.gov.ge>
Subject : Fwd: Activity 2.1.1 - follow-up
Cc : Vladimer Getia <khgetia@gmail.com>
Received On : 14.07.2020 08:42
Attachments :
ძვირფასო კოლეგებო,

ლიეტუველმა ექსპერტებმა გვთხოვეს, ვუპასუხოთ მათ რამოდენიმე კითხვას, რომლებიც ქვემოთ არის მოცემული. 

Dear Keti, would you be so kind to answer a few questions for me and Laimutė:

  1. Are both Regulatory Agency and NCDC under the MoH?
  2. If licensing of BE is moved to Regulatory Agency, what will be the future for Transfusiology subgroup in MoH? Who would be responsible for policy of transfusiology in MoH?
  3. If licenses for BE are issued by the MoH, and licenses of other health care institutions are issued by Regulatory Agency, are they somehow different? Do licensing requirements differ as well?
  4. Does MoH of Georgia issue licenses only for BE or are there other health care services licensed by MoH?

უმორჩილესად გთხოვთ, პასუხები შეძლებისდაგვარად მოკლე დროში გამოგვიგზავნოთ.  

მადლობას გიხდით წინასწარ დახმარებისთვის,
პატივისცემით,
ქეთი



---------- Forwarded message ---------
From: <agne.kaminskiene@kraujodonoryste.lt>
Date: Tue, Jul 14, 2020 at 11:35 AM
Subject: RE: Activity 2.1.1 - follow-up
To: Keti Khizanishvili <keti.khizanishvili@gmail.com>, Smid, Martin <M.Smid@sanquin.nl>, Ardenne-Stachiw, Olenka van <O.vanArdenne@sanquin.nl>, Laimutė Stonienė <l.stoniene@kraujodonoryste.lt>, Wim de Kort <wimdekort1952@gmail.com>
Cc: Amiran Gamkrelidze <a.gamkrelidze@ncdc.ge>, turkia babilina <bturkia@yahoo.com>, Vladimer Getia <khgetia@gmail.com>, Algirdas Gri <algirdasgris@gmail.com>, Kakhaber Dvalidze <kakha99@gmail.com>


Dear Keti and other colleagues,

 

We also appreciate the opportunity to participate in round table discussions. We understand that Georgian colleagues need a few days to discuss and decide on the organizational structure of future institution. Under those circumstances we agree moving our discussions to Friday.

 

Dear Keti, would you be so kind to answer a few questions for me and Laimutė:

  1. Are both Regulatory Agency and NCDC under the MoH?
  2. If licensing of BE is moved to Regulatory Agency, what will be the future for Transfusiology subgroup in MoH? Who would be responsible for policy of transfusiology in MoH?
  3. If licenses for BE are issued by the MoH, and licenses of other health care institutions are issued by Regulatory Agency, are they somehow different? Do licensing requirements differ as well?
  4. Does MoH of Georgia issue licenses only for BE or are there other health care services licensed by MoH?

Thank you very much in advance.

 

 

 

Best regards,

Agnė Kaminskienė

Lawyer

 

VšĮ Nacionalinis kraujo centras

Žolyno g. 34, LT-10210, Vilnius

Tel. +37068312545

agne.kaminskiene@kraujodonoryste.lt

http://www.kraujodonoryste.lt

 

 

From: Keti Khizanishvili <keti.khizanishvili@gmail.com>
Sent: Monday, July 13, 2020 3:01 PM
To: Smid, Martin <M.Smid@sanquin.nl>; agne.kaminskiene@kraujodonoryste.lt; Ardenne-Stachiw, Olenka van <O.vanArdenne@sanquin.nl>; Laimutė Stonienė <l.stoniene@kraujodonoryste.lt>; Wim de Kort <wimdekort1952@gmail.com>
Cc: Amiran Gamkrelidze <a.gamkrelidze@ncdc.ge>; turkia babilina <bturkia@yahoo.com>; Vladimer Getia <khgetia@gmail.com>; Algirdas Gri <algirdasgris@gmail.com>; Kakhaber Dvalidze <kakha99@gmail.com>
Subject: Activity 2.1.1 - follow-up

 

Dear experts,

 

First of all, I would like to thank you all for participating in today's teleconference.

 

We would like to offer you to organize the second day of activity 2.1.1 at the end of this week, on July 17th. During the next three days the Georgian working group members will have internal discussions regarding the draft legislation on blood safety, as well as the organizational structure of future institution.

 

Would you kindly suggest, as Dr. Gamkrelidze asked you all, tentative functionalities of the future blood safety system monitoring organization or unit, given that the three major players will be: a. Ministry of Health, b. Regulatory Agency, c. NCDC.

 

What are potential challenges if the future NCA operates under each of these three bodies?

 

What should we pay special attention to?

 

We do not want to overstretch ourselves  but the more detailed your suggestions are, the more immensely grateful we will be. We understand that the burden of making decisions is entirely upon the Georgian side, but your expert advices will be invaluable in helping us make that decision.

 

If necessary, we can provide you with very thorough information and relevant current functions about all three institutions.

 

Thank you in advance,

 

With Regards,

Keti

 

Ketevan Khizanishvili

RTA Assistant

Twinning Project Strengthening Blood Safety System in Georgia

Mob: (+995) 599 155 00